The biotech company said in its first-quarter earnings report that the investigational new drug application that it filed with the Food and Drug Administration last week had been cleared. The Phase I study has enrolled three dose cohorts, with six additional ones planned.

LEAVE A REPLY

Please enter your comment!
Please enter your name here